Section 3 explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
The rest of paragraphs 9 and 10 of the Pharmaceutical Patent Guidelines (October 2014) cover industrial applicability and six more exclusions in section 3, apart from section 3(d), which has its own article. The most useful parts for applicants are the synergy requirement for compositions under section 3(e) and the warning that treatment methods are caught when disguised as compositions.
The specification must show usefulness in a distinct and credible manner (9.1). Compounds isolated from nature are excluded by section 3(c), though processes of isolation may qualify (10.2). A composition passes section 3(e) only if its components interact to give a combined effect greater than the sum of their individual effects (10.16). Methods of treatment are excluded by section 3(i) even if worded as compositions (10.20). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from October 2014. For the same exclusions in the Manual, see our article on section 3(a), (b), (c), (e) and (f) and the one on section 3(h), (i) and (j); the general summary is in what cannot be patented under section 3. A claim set facing a section 3 objection can be redrafted with a patent objection reply.
Industrial applicability (paragraph 9)
Paragraph 9.1 ties industrial applicability to usefulness, noting that section 64(1)(g) makes a patent liable to revocation if the invention is not useful. The specification should disclose usefulness and industrial applicability in a distinct and credible manner unless already established, explicitly or implicitly. A practical application and industrial use must be disclosed, with a concrete benefit derivable from the description and common general knowledge. Speculative use will not do.
The Guidelines give two illustrations.
- Synthetic analogues of a steroid whose only stated interest is that they are being investigated because they resemble known active compounds: not patentable as there is no credible and specific utility. Scientific interest does not make a claim patentable.
- Two compounds A and B and a process that separates A from B: the specification gives a use for A only. The claim to B is not allowable, because it has no shown utility; being a by-product of making A does not make it patentable.
Section 3(b): public order, morality and harm to life or environment (10.1)
Inventions whose primary or intended use or commercial exploitation would be contrary to public order or morality, or would seriously prejudice human, animal or plant life or health or the environment, are not allowable. The Guidelines justify this on the footing that a patent is a reward in the form of a monopoly, which is not justified if it is prejudicial to the public interest. No example is given in the pharmaceutical Guidelines.
Section 3(c): discoveries (10.2 and 10.3)
Scientific principles, abstract theories and discovery of living or non-living substances occurring in nature are excluded. Compounds isolated from nature are not patentable, but processes of isolation can be considered under section 2(1)(j). Two examples:
- A compound for cardiac disorder obtained from a marine animal's fluid: not patentable, being a non-living substance occurring in nature.
- A plant extract containing cardiac glycosides with anticancer effect in cell-line tests: excluded as a discovery of a non-living substance occurring in nature.
The lesson is that showing a useful activity of a natural extract does not turn the extract into an invention; a claim has to be to something made, not found.
Section 3(e): mere admixture (10.12 to 10.17)
The Guidelines state the principle: old integers placed side by side, each performing its own function independently, are not a patentable combination; but where they work together with an interrelation producing a new or improved result, there is patentable subject matter in the working interrelation. They cite Ram Pratap v Bhabha Atomic Research Centre, as cited in the Guidelines, for the point that a mere juxtaposition of known features arbitrarily chosen from several possible combinations is not an invention.
The working rule is in 10.16: a composition made by mere admixture that aggregates the properties of its components is not patentable. If the functional interaction achieves a combined technical effect greater than the sum of the individual effects, it is more than a mere aggregation.
| Example in the Guidelines | Outcome | Reason |
|---|---|---|
| A composition of two known pain and fever medicines, to control pain and inflammation | Not patentable under 3(e) | Both are known for their activity and the application is silent on any combined effect over the sum of individual effects |
| A composition of a known active salicylate in a stated dose range with an inert carrier | Not patentable | The active and carrier are known and the carrier plays no role in enhancing the activity: an aggregation |
For an applicant, the practical step is to put comparative data in the specification: the combination against each component alone, at doses that allow a conclusion about synergy.
Section 3(i): methods of treatment (10.18 to 10.21)
The Guidelines list, as stated in the Manual, what is excluded: medicinal, surgical, curative, prophylactic, diagnostic and therapeutic methods, and methods of treating animals to rid them of disease or increase their economic value. They list examples such as administering medicines, vaccination, diagnosis, and operations requiring a surgeon's skill, and note that applying substances for purely cosmetic purposes is not therapy, and that surgical, therapeutic or diagnostic instruments and prostheses may be patented.
Two further points matter for drug applicants.
- Treatment methods disguised as compositions. The Guidelines say methods of treatment are often claimed in the guise of composition claims, and that when such claims are converted to product claims during examination, the amendments are examined under section 57 read with section 59.
- The example. A claim to a method of treating cancer by administering a combination of two named agents, simultaneously or sequentially, in several cancers, falls within section 3(i) as directed to a method of treatment.
Our posts on section 57 and the Manual's chapter on section 3(h) to (j) go further on these points.
Section 3(j) and 3(p) (10.22 to 10.25)
The Guidelines incorporate by reference the relevant parts of the Biotechnology Guidelines and the Traditional Knowledge Guidelines. They record three points.
- Plants and animals, including parts such as seeds, are not patentable, except micro-organisms. Read with section 3(c), micro-organisms occurring in nature are not patentable, so only genetically modified micro-organisms qualify.
- Section 3(p) excludes an invention that in effect is traditional knowledge or an aggregation or duplication of known properties of traditionally known components.
- The examples: a claim to treating an inflammatory bowel disease with an extract of a named medicinal plant containing four named constituents is excluded under section 3(p), because a published article records traditional treatment of gastro-intestinal disorders with that plant in a district of Gujarat; and a pharmaceutical composition whose active ingredient is an antigen-presenting cell (a dendritic cell or macrophage) expressing a tumour protein portion is objected to under section 3(j), since the cell is the active ingredient even though the claim is worded as a composition.
The related guidelines are explained in our articles on the traditional knowledge principles and the biotechnology treatment of section 3(h) to (p).
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Does the specification show a distinct and credible use for each claimed compound? | Utility data or a stated use for every compound claimed, including intermediates and by-products |
| Is the substance isolated from nature? | A claim to a modified substance, a process of isolation or a formulation, not the natural substance |
| Is the composition more than the sum of its parts? | Comparative data showing synergy |
| Is the claim a treatment method in disguise? | Claims to the product or composition itself, with use stated only where allowed |
| Is the invention in effect traditional knowledge? | Evidence of an effect or construction that the traditional source does not disclose |
A worked example (invented)
Ayuvriddhi Pharma claims a tablet combining two known herbal constituents, saying that the combination treats joint pain. The examiner objects under sections 3(e) and 3(p). Ayuvriddhi files data from a dose-matrix study in which the combination reduces pain markers at lower doses than either constituent alone, and cites its description of the interaction between the two. It also states that the traditional texts it knows of do not describe the combination. The reply addresses synergy directly, as 10.16 requires, and answers the traditional knowledge point with evidence.
Common lapses
- Claiming every compound in a reaction without a use for each.
- Claiming a natural extract as a composition without any process or modification.
- Offering a combination without comparative data.
- Writing a method of treatment as "a composition for use in".
Need help with a section 3 objection on a drug claim?
Section 3 objections on compositions and extracts are usually answered with data and a redraft of the claims. Our team can assess your specification and prepare the reply. See patent objection reply, and read next on sufficiency and clarity under paragraph 11.
Key takeaways
- The specification must show credible, specific utility for each claimed compound.
- Natural compounds and extracts are excluded as discoveries; isolation processes may qualify.
- Compositions need synergy beyond the sum of the parts to pass section 3(e).
- Treatment methods remain excluded in whatever form they are worded.
- Plant and traditional knowledge claims are checked under sections 3(j) and 3(p), with the related guidelines incorporated by reference.
Read next
- Pharmaceutical Patent Guidelines 2014, paragraph 10: section 3(d)
- Pharmaceutical Patent Guidelines 2014, paragraph 11: sufficiency, clarity and support
- Manual Chapter 9: section 3(h), (i) and (j)
- What Cannot Be Patented: Section 3
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.